

Conference call regarding interim report Q2

Invitation to attend Surgical Science's conference call regarding presentation of the interim report January-June 2024. The presentation will be held in English.

Time: Thursday, August 22 at 11:00 a.m. CET

If you wish to participate via webcast, please use the link below. It will be possible to ask written questions via the webcast.

<https://ir.financialhearings.com/surgical-science-sweden-q2-report-2024>

If you wish to participate via teleconference, please register via the link below. After registration, you will receive phone numbers and a conference ID to access the conference. It will be possible to ask oral questions via the telephone conference.

<https://conference.financialhearings.com/teleconference/?id=50048962>

Participants from Surgical Science are:

Gisli Hennermark, CEO

Anna Ahlberg, CFO

A press release with Surgical Science's interim report for January-June 2024 will be published on August 22, 2024 at 07:30 a.m. CET.

Prior to the start of the conference call, presentation material will be available on the company's website, under Investors, Presentations.

Gothenburg, Sweden, August 12, 2024

Surgical Science Sweden AB (publ)

The press release, in its entirety, is available through the attachment or via:

<https://surgicalscience.com/investor-relations/#press-releases>

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

For further information, please contact:

Gisli Hennermark, CEO

Telephone: +46-70-420 83 00

E-mail: gisli.hennermark@surgicalscience.com

Anna Ahlberg, CFO

Telephone: +46-70-855 38 35

E-mail: anna.ahlberg@surgicalscience.com

About Surgical Science Sweden AB (publ)

One of the biggest challenges within healthcare globally is reducing injuries incurred during care. Medical education and training are key, especially as a large part of the training can now be performed outside the operating room. Surgical Science is a world leader in the development of virtual reality simulators for evidence-based training. The simulators enable surgeons and other medical specialists to train and improve their psycho-motor skills and instrument handling before entering the clinical environment. Alongside its own products, Surgical Science works with simulation solutions for medical device companies that develop instruments for clinical use, such as robotic surgery.

Surgical Science has approximately 260 employees. The company is headquartered in Gothenburg, Sweden and also has operations in Tel Aviv, Israel, as well as in Stockholm, Sweden and in Seattle and Cleveland, US. Through sales offices in the US and China as well as a global network of distributors, Surgical Science maintains a presence in most markets. Shares in Surgical Science Sweden AB (publ) are traded on Nasdaq First North Growth Market. Certified Adviser is Carnegie Investment Bank AB (publ).

Attachments

[Conference call regarding interim report Q2](#)